What is AOA Dx?
AOA Dx is a medical technology firm dedicated to the development of the first accurate, non-invasive diagnostic test for early-stage ovarian cancer. By leveraging advanced biomarker research, the company aims to improve patient outcomes, reduce mortality rates, and provide significant cost efficiencies for healthcare payers. Positioned at the intersection of oncology and diagnostic innovation, AOA Dx is currently scaling its operations to transition from research-heavy development into clinical validation and market entry, addressing a critical gap in women's health diagnostics.
How much funding has AOA Dx raised?
AOA Dx has raised a total of $24M across 2 funding rounds:
Angel/Seed
$7M
Other Financing Round
$17M
Angel/Seed (2022): $7M with participation from Pioneer Fund, Beacon Angels, The Helm Management, AlleyCorp companies, Kyto Technology & Life Science, Joyance Partners, RH Capital, Avestria Ventures Management, Launchpad Venture Group, SideCar Angels, and TBD Angels
Other Financing Round (2023): $17M led by Good Growth Capital, RH Capital, and Y Combinator
Key Investors in AOA Dx
Pioneer Fund
A venture firm composed of Y Combinator alumni that provides capital, strategic guidance, and extensive networking support to early-stage startups.
Beacon Angels
A Boston-based angel investment group that facilitates early-stage funding and provides strategic relationships for high-growth companies.
Y Combinator
A premier startup accelerator and seed-stage investor that provides funding and mentorship to high-potential technology companies.
What's next for AOA Dx?
With the recent infusion of capital, AOA Dx is well-positioned to accelerate its clinical trial roadmap and refine its diagnostic platform. The strategic focus will likely shift toward regulatory milestones and the establishment of commercial partnerships necessary for widespread clinical adoption. As the company moves beyond its initial seed-stage foundations, the primary objective remains the successful commercialization of its diagnostic test, which requires rigorous evidence-based validation to satisfy both clinical practitioners and institutional payers. Continued support from its diverse investor base, which includes specialized life science venture firms and angel collectives, provides the necessary operational guidance to navigate the complex regulatory landscape of the diagnostic industry.
See full AOA Dx company page
